home / stock / azn / azn news


AZN News and Press, AstraZeneca PLC From 01/22/24

Stock Information

Company Name: AstraZeneca PLC
Stock Symbol: AZN
Market: NYSE
Website: astrazeneca.com

Menu

AZN AZN Quote AZN Short AZN News AZN Articles AZN Message Board
Get AZN Alerts

News, Short Squeeze, Breakout and More Instantly...

AZN - AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma

Adults living with asthma now have an approved rescue treatment designed to treat both symptoms and inflammation to help prevent asthma attacks AstraZeneca announces AIRSUPRA ® (albuterol/budesonide), is now commercially available in the US by prescription. AIRSUPRA recei...

AZN - Week In Review: Lee's Pharm Signs $138M Agreement For China Rights To Heart Failure Therapy

2024-01-21 01:55:00 ET Summary Lee’s Pharm acquired China rights to a heart failure therapy from Windtree Therapeutics. AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech Development Zone to build a new production line in its ...

AZN - AstraZeneca reports positive liver cancer study results for Imfinzi

2024-01-19 16:55:40 ET More on AstraZeneca Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca Is Feeling The Weight Of The Market In 2023 AstraZeneca PNH drug gets firs...

AZN - AstraZeneca PNH drug gets first regulatory approval in Japan

2024-01-19 16:36:53 ET More on AstraZeneca Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca Is Feeling The Weight Of The Market In 2023 Icosavax ticks lower as HSR fi...

AZN - Icosavax ticks lower as HSR filing for AstraZeneca deal withdrawn, refiled

2024-01-19 10:13:55 ET More on Icosavax Icosavax CVR Seems Fairly Valued AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition Icosavax deal CVR based on FDA approval for IVX-A12, sales in EU, UK, Canada Biggest stock movers today: Oracle, Workhorse ...

AZN - IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization

EMERALD-1 is first global Phase III trial to show improved clinical outcome for systemic therapy in combination with TACE in this setting Positive results from the EMERALD-1 Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab) in combination with TACE and be...

AZN - Eli Lilly's Jaypirca to lead BTK inhibitor market for leukemia

2024-01-18 13:25:54 ET Eli Lilly’s ( NYSE: LLY ) new cancer therapy, Jaypirca (pirtobrutinib), is expected to dominate the market for BTK inhibitors for chronic lymphocytic leukemia (CLL) in seven major markets, data and analytics firm GlobalData said  Friday. BTK in...

AZN - Pfizer faces setback in Enhertu patent dispute with Daiichi

2024-01-17 07:08:09 ET More on Pfizer Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort Pfizer Inc. (PFE) J.P. Morgan 42nd Annual Healthcare Conference (Transcript) Pfizer: 50% Down From The Highs, Generous Dividend, And Robust Balance Sheet First RSV...

AZN - First RSV shots, groundbreaking gene therapy among 2024 drugs to watch

2024-01-14 12:00:24 ET More on CRISPR, GSK, etc. Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) ...

AZN - Cytokinetics plunges amid no deal announcement as JPMorgan conf set to end

2024-01-11 11:19:54 ET More on Cytokinetics Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3 Trial (Upgrade) Cytokinetics: Buyout Rumors Ahead Of The Key Phase 3 Readout Of Aficamten Cytokinetics, Incorporated (CYTK) Q3 2023 Earnings Call Transcript ...

Previous 10 Next 10